Influenza Clinical Trial
Official title:
Efficacy of Sambucol on the Length of Time to Resolution of Influenza Illness
The trial will examine the efficacy of sambucol in the treatment of influenza. The primary efficacy endpoint will be the length of time to resolution of influenza illness.The double blind trial will be conducted at the Personnel Clinic, and at the Clinical virology Unit, Hadassah University Hospital, and will include 100 patients with laboratory-confirmed influenza infection, 50 in the sambucol and 50 in the placebo study arm.
The trial will be conducted at the Personnel Clinic, and at the Clinical virology Unit,
Hadassah University Hospital.
Candidates for participation in the trial :
Patients who will present at the clinic with influenza-like symptoms; men and women ages 20
yrs- 65 yrs who will sign written informed consent
Excluded from the trial will be:
- Pregnant women or women who cannot exclude pregnancy.
- Patients with diabetes.
- Immune-suppressed patients, including patients taking immunosuppressive drugs.
- Patients with renal failure.
- Patients who received the recent influenza vaccine.
The study participants will receive treatment (either Sambucol or placebo) for five days. The
follow-up period will be 10 days. All patients initially included in the trial will be
followed for 10 days.
Inclusion criteria:
- Fever ≥ 380C.
- The presence of at least one of the following respiratory symptoms: cough, sore throat,
nasal congestion/ runny nose.
- The presence of at least one of the following systemic symptoms: headache, fatigue,
myalgia, chills/sweats, malaise.
Study Patients A total of 100 patients with laboratory-confirmed influenza infection will be
included in the study (50 in each study arm).
This calculation is based on the expected percentage of recovery within 3 days from initial
treatment (allowing that 80% of patients given the active component will show improvement as
opposed to 50% of placebo patients).
Assuming that 50% of the patients presenting with influenza-like illness will have a
laboratory-confirmed influenza infection, a total number of 200 patients is expected.
The primary efficacy endpoint will be the length of time to resolution of influenza illness
(defined as the period from start of study drug to the relief of symptoms).
Study design:
1. Patients presenting at the clinic with the above indicated inclusion criteria will be
referred by the clinic nurse to a physician to establish the diagnosis
2. The temperature, the presence and severity of influenza symptoms including cough, nasal
obstruction, sore throat, fatigue, headache, myalgia will be recorded on a four-point
scale (0-absent, 1-mild, 2-moderate, 3-severe). Patients will also record their ability
to do their normal activities, overall health status, and sleep quality on a ten-point
scale (0-unable or worst, to 10-fully able, best)
3. For influenza detection, nose and throat swabs will be collected at baseline.
4. Patients will be randomly assigned to receive either Sambucol or placebo (15 cc 4 times
daily for 5 days).
5. Patients will be instructed that relief medications (Acamol /Optalgin) will be taken
only as required, and that their use should be recorded.
6. The follow-up will include all the parameters (see "2") recorded daily at days 1-5, at
day 7, and at day 10.
7. Compliance with the study drug will be recorded.
8. In case the patient's condition deteriorates, the patient will be examined at the clinic
to rule out the presence of complications (such as pneumonia, sinusitis, or bronchitis).
9. Statistical analysis will include the duration and severity of the symptoms as well as
the use of relief medications.
Laboratory diagnosis of influenza infection:
Combined nose and throat specimens will be tested for the presence of influenza virus at the
Clinical Virology Unit by real-time PCR, following viral RNA extraction, using the TaqMan ABI
7900 instrument. Primers and fluorescent probes specific for influenza A and B viruses will
be employed in a multiplex reaction.
Specimens found positive for influenza by real-time PCR will be further subjected to
influenza culture on MDCK cells.
The recovered influenza viruses will be subtyped by hemagglutination inhibition, using
specific antisera obtained from the WHO, or by multiplex reverse transcription (RT)- PCR
reaction, using specific primers for influenza B as well as for the different influenza A H
and N.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05523089 -
The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults
|
Phase 2 | |
Completed |
NCT05009251 -
Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake
|
N/A | |
Completed |
NCT03282240 -
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
|
Phase 3 | |
Completed |
NCT00971425 -
Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)
|
Phase 3 | |
Completed |
NCT00968526 -
Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT00968539 -
Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT05525494 -
Patient Portal Flu Vaccine Reminders (5)
|
N/A | |
Completed |
NCT04074928 -
Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects
|
Phase 3 | |
Completed |
NCT04695717 -
This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam
|
Phase 3 | |
Completed |
NCT05012163 -
Lottery Incentive Nudges to Increase Influenza Vaccinations
|
N/A | |
Completed |
NCT03888989 -
Response to Influenza Vaccine During Pregnancy
|
Phase 1 | |
Completed |
NCT04109222 -
Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively
|
Phase 4 | |
Completed |
NCT02587221 -
Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age
|
Phase 3 | |
Completed |
NCT03453801 -
The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection
|
Phase 1 | |
Completed |
NCT01440387 -
A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older
|
Phase 3 | |
Terminated |
NCT01195779 -
Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children
|
Phase 2 | |
Completed |
NCT03321968 -
Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults
|
Phase 3 | |
Completed |
NCT00972517 -
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children
|
Phase 3 | |
Completed |
NCT04570904 -
Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
|
||
Recruiting |
NCT03331991 -
Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel
|
N/A |